Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amarin
Pharma
In a big win for generics drugmakers, SCOTUS sides with Hikma
The U.S. Supreme Court has sided with Hikma, ruling that its generic version of Amarin’s Vascepa does not infringe patents held by the Irish company.
Kevin Dunleavy
Jun 4, 2026 3:11pm
Top US lawyer urges SCOTUS to toss Amarin 'skinny label' case
Feb 27, 2026 10:15am
SCOTUS to hear 'skinny label' case between Amarin, Hikma
Jan 20, 2026 11:54am
Amarin sells Vascepa's rights in Europe to Recordati for $25M
Jun 24, 2025 11:26am
Investor group calls for strategy shift at struggling Amarin
Mar 20, 2025 11:00am
Amarin, after stock crash and layoffs, revives patent lawsuit
Jun 26, 2024 1:01pm
